Biogen (BIIB)
| Company | Ticker | Sector | Industry | Quality | PAR |
|---|---|---|---|---|
| Biogen | BIIB | Healthcare | Drug Manufacturers - General | 84 | 6.4% |
| Current Price (02/24) | $282.74 | |||
| CAPS Rating (Rate this stock on CAPS) |  |
|||
| Expected Income Statement | ||||
| Current Sales | 13,750.0 | |||
| Sales Growth Forecast | 4.1% | |||
| Net Profit Margin | 29.2% | |||
| Projected Shares Outstanding | 140.00 | |||
| EPS - Five year Forecast | $35.13 | |||
| Average P/E Ratio | 11.0 | |||
| Projected Average Price | $386.46 | |||
| Price Appreciation (Annualized) | 6.4% | |||
| Annual Dividend Yield | 0.0% | |||
| Projected Annual Return | 6.4% | |||
| Quality | ||||
| Financial Strength | 90 | 22.6 | ||
| EPS Stability | 82 | 20.5 | ||
| Industry Sales Growth Rate | 8.0% | 6.5 | ||
| Industry Net Profit Margin | 22.5% | 16.2 | ||
| Calculated Quality Rating | 65.8 | |||
| Fool CAPS | ||||
Total Players
973
Outperforms
71
Underperforms
All-Stars (228)
215
Outperforms (94%)
13
Underperforms
|
||||
| Fundamental Data Updated: 01/01/2021 | ||||